Other animals
Laboratory and other animal studies held in the database.
This page lists published studies. It reports what the authors did and found, with the limits of each study. It is not advice.
25 studies listed, newest first.
- Investigating Properties of Palmitoylethanolamide in Physiology and Disease: Far Beyond an Anti-Inflammatory ShieldReviewHumansOther animals
- Chronic palmitoylethanolamide administration via slow-release subcutaneous pellets promotes neuroprotection and mitigates neuroinflammation in the Tg2576 mouse model of Alzheimer's diseaseLaboratory studyOther animals
- Palmitoylethanolamide causes dose-dependent changes in brain function and the lipidomeLaboratory studyOther animals
- Palmitoylethanolamide in Postmenopausal Metabolic Syndrome: Current Evidence and Clinical PerspectivesReviewHumansOther animals
- Palmitoylethanolamide counteracts high-fat diet-induced gut dysfunction by reprogramming microbiota composition and affecting tryptophan metabolismLaboratory studyOther animals
- Synaptic Effects of Palmitoylethanolamide in Neurodegenerative DisordersReviewHumansOther animalsWith luteolin
- Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese miceLaboratory studyOther animals
- Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to HumansReviewHumansOther animals
- Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory PainLaboratory studyOther animalsWith acetyl-L-carnitine
- Palmitoylethanolamide Modulation of Microglia Activation: Characterization of Mechanisms of Action and Implication for Its Neuroprotective EffectsLaboratory studyOther animals
- Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer's DiseaseLaboratory studyOther animals
- Palmitoylethanolamide: Prenatal Developmental Toxicity Study in RatsLaboratory studyOther animals
- Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patientsReviewHumansOther animals
- Impaired Duodenal Palmitoylethanolamide Release Underlies Acid-Induced Mast Cell Activation in Functional DyspepsiaLaboratory studyHumansOther animals
- An Update of Palmitoylethanolamide and Luteolin Effects in Preclinical and Clinical Studies of Neuroinflammatory EventsReviewHumansOther animalsWith luteolin
- ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic PainReviewHumansOther animals
- The Basal Pharmacology of PalmitoylethanolamideReviewHumansOther animals
- Co-ultraPEALut: Role in Preclinical and Clinical Delirium ManifestationsControlled trialHumansOther animalsWith luteolin
- Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic EffectLaboratory studyOther animals
- A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain modelsLaboratory studyOther animalsWith quercetin
- The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulationsReviewHumansOther animals
- Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to ManObservational studyHumansOther animalsWith luteolin
- The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channelsLaboratory studyHumansDogsOther animals
- Adelmidrol increases the endogenous concentrations of palmitoylethanolamide in canine keratinocytes and down-regulates an inflammatory reaction in an in vitro model of contact allergic dermatitisLaboratory studyDogsOther animals
- Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in ratsLaboratory studyOther animals